Home › Companies › NURIX THERAPEUTICS INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and NURIX THERAPEUTICS INC.’s Form 8-K, filed May 19, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 19, 2025: 5 items on NURIX THERAPEUTICS INC.’s Form 8-K, filed May 19, 2025: 3 elected · 2 approved.
Significant dissent: 1 director (28.8% against).
Notable dissent: 1 director (17.8% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Rubric Capital (13F, 4.5%, as of September 30, 2026)
Explore NURIX THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are NURIX THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 19, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Judith A. Reinsdorf | 43,571,416 | -- | -- | 17,651,464 | 3,833,317 | 71% | Elected | — |
| Elect Director: Edward C. Saltzman | 50,302,518 | -- | -- | 10,920,362 | 3,833,317 | 82% | Elected | — |
| Elect Director: Roy D. Baynes | 60,821,712 | -- | -- | 401,168 | 3,833,317 | 99.3% | Elected | — |
| 2. Ratification of Appointment of Independent Registered Public Accounting Firm | 64,950,599 | 85,040 | 20,558 | -- | -- | 99.9% | Approved | — |
| 3. Approval, on a Non-binding Advisory Basis, of the Compensation of the Company's Named Executive Officers | 49,788,975 | 11,341,365 | 92,540 | -- | 3,833,317 | 81% | Approved | — |
Source: NURIX THERAPEUTICS INC., Form 8-K, filed with the SEC on May 19, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
203 asset managers disclosed a vote on at least one NURIX THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
71% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Judith A. Reinsdorf
NURIX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Judith A. Reinsdorf”): 43,571,416 for, 17,651,464 withheld, per its Form 8-K filed May 19, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the three nominees for director was elected to serve until the Company's 2028 annual meeting of stockholders and until his or her successor has been elected and qualified, or until his or her earlier resignation or removal.”
Support: 71% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 64 asset managers below reported 17,785,352 for, 9,986,181 withheld, 41,376 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 1,451,235 | 0 | 0 | 9,024,776 | Mixed |
| Vanguard | 4,107,266 | 0 | 0 | 0 | For |
| BlackRock | 3,890,098 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,294,671 | 0 | 0 | 0 | For |
| ARK ETF Trust | 1,538,187 | 0 | 0 | 0 | For |
| Charles Schwab | 551,228 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 534,580 | 0 | 0 | 0 | For |
| Artisan | 448,628 | 0 | 0 | 0 | For |
| Hartford | 432,350 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 212,000 | 0 | 0 | 0 | For |
| State Street | 209,421 | 0 | 0 | 188 | For |
| Dimensional | 0 | 0 | 0 | 206,716 | Withhold |
| Equitable | 125,538 | 0 | 0 | 63,320 | Mixed |
| Victory Capital | 1,578 | 0 | 0 | 177,221 | Withhold |
| TIAA | 160,469 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 118,386 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 114,985 | Withhold |
| Northwestern Mutual | 95,038 | 0 | 0 | 0 | For |
| Lincoln Financial | 51,300 | 0 | 0 | 38,415 | Mixed |
| Russell Investments | 85,053 | 0 | 0 | 0 | For |
| John Hancock | 45,962 | 0 | 24,422 | 0 | Mixed |
| MassMutual | 70,239 | 0 | 0 | 0 | For |
| Tema ETF Trust | 59,146 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 0 | 52,576 | Withhold |
| RBB FUND, INC. | 0 | 0 | 0 | 52,098 | Withhold |
Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
82% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Edward C. Saltzman
NURIX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Edward C. Saltzman”): 50,302,518 for, 10,920,362 withheld, per its Form 8-K filed May 19, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the three nominees for director was elected to serve until the Company's 2028 annual meeting of stockholders and until his or her successor has been elected and qualified, or until his or her earlier resignation or removal.”
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 63 asset managers below reported 18,438,796 for, 9,321,346 withheld, 10,767 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 1,451,235 | 0 | 0 | 9,024,776 | Mixed |
| Vanguard | 4,107,266 | 0 | 0 | 0 | For |
| BlackRock | 3,890,098 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,294,671 | 0 | 0 | 0 | For |
| ARK ETF Trust | 1,538,187 | 0 | 0 | 0 | For |
| Charles Schwab | 551,228 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 534,580 | 0 | 0 | 0 | For |
| Artisan | 448,628 | 0 | 0 | 0 | For |
| Hartford | 432,350 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 212,000 | 0 | 0 | 0 | For |
| State Street | 209,609 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 206,716 | Withhold |
| Equitable | 125,538 | 0 | 0 | 63,320 | Mixed |
| Victory Capital | 178,799 | 0 | 0 | 0 | For |
| TIAA | 160,469 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 118,386 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 114,985 | 0 | 0 | 0 | For |
| Northwestern Mutual | 95,038 | 0 | 0 | 0 | For |
| Lincoln Financial | 88,436 | 0 | 0 | 1,279 | For |
| Russell Investments | 85,053 | 0 | 0 | 0 | For |
| John Hancock | 70,384 | 0 | 0 | 0 | For |
| MassMutual | 70,239 | 0 | 0 | 0 | For |
| Tema ETF Trust | 59,146 | 0 | 0 | 0 | For |
| Northern Trust | 52,576 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 52,098 | 0 | 0 | 0 | For |
Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99.3% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Roy D. Baynes
NURIX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Roy D. Baynes”): 60,821,712 for, 401,168 withheld, per its Form 8-K filed May 19, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors Each of the three nominees for director was elected to serve until the Company's 2028 annual meeting of stockholders and until his or her successor has been elected and qualified, or until his or her earlier resignation or removal.”
Support: 99.3% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 63 asset managers below reported 27,534,237 for, 225,905 withheld, 10,767 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,476,011 | 0 | 0 | 0 | For |
| Vanguard | 4,107,266 | 0 | 0 | 0 | For |
| BlackRock | 3,890,098 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,294,671 | 0 | 0 | 0 | For |
| ARK ETF Trust | 1,538,187 | 0 | 0 | 0 | For |
| Charles Schwab | 551,228 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 534,580 | 0 | 0 | 0 | For |
| Artisan | 448,628 | 0 | 0 | 0 | For |
| Hartford | 432,350 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 212,000 | 0 | 0 | 0 | For |
| State Street | 209,609 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 206,716 | Withhold |
| Equitable | 188,858 | 0 | 0 | 0 | For |
| Victory Capital | 178,799 | 0 | 0 | 0 | For |
| TIAA | 160,469 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 118,386 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 114,985 | 0 | 0 | 0 | For |
| Northwestern Mutual | 95,038 | 0 | 0 | 0 | For |
| Lincoln Financial | 88,436 | 0 | 0 | 1,279 | For |
| Russell Investments | 85,053 | 0 | 0 | 0 | For |
| John Hancock | 70,384 | 0 | 0 | 0 | For |
| MassMutual | 70,239 | 0 | 0 | 0 | For |
| Tema ETF Trust | 59,146 | 0 | 0 | 0 | For |
| Northern Trust | 52,576 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 52,098 | 0 | 0 | 0 | For |
Showing the 25 largest of 63 asset managers. All 63 are in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
81% Approved · of votes cast
Prior year: 88.3% for (May 20, 2024 meeting) ▼ 6.8 pts
Description as filed by funds: To approve, a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.
NURIX THERAPEUTICS INC.’s own tally for this item (“3. Approval, on a Non-binding Advisory Basis, of the Compensation of the Company's Named Executive Officers”): 49,788,975 for, 11,341,365 against — passed, per its Form 8-K filed May 19, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3. Approval, on a Non-binding Advisory Basis, of the Compensation of the Company's Named Executive Officers”
Support: 81% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 1,451,235 | 9,024,776 | 0 | 0 | Mixed |
| Vanguard | 4,107,266 | 0 | 0 | 0 | For |
| BlackRock | 3,890,098 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,294,671 | 0 | 0 | 0 | For |
| ARK ETF Trust | 1,538,187 | 0 | 0 | 0 | For |
| Charles Schwab | 551,228 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 534,580 | 0 | 0 | 0 | For |
| Artisan | 448,628 | 0 | 0 | 0 | For |
| Hartford | 432,350 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 212,000 | 0 | 0 | 0 | For |
| State Street | 209,566 | 43 | 0 | 0 | For |
| Dimensional | 206,716 | 0 | 0 | 0 | For |
| Equitable | 188,858 | 0 | 0 | 0 | For |
| Victory Capital | 178,799 | 0 | 0 | 0 | For |
| TIAA | 160,469 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 118,386 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 114,985 | 0 | 0 | 0 | For |
| Northwestern Mutual | 95,038 | 0 | 0 | 0 | For |
| Lincoln Financial | 89,715 | 0 | 0 | 0 | For |
| Russell Investments | 85,053 | 0 | 0 | 0 | For |
| John Hancock | 70,384 | 0 | 0 | 0 | For |
| MassMutual | 70,239 | 0 | 0 | 0 | For |
| Tema ETF Trust | 59,146 | 0 | 0 | 0 | For |
| Northern Trust | 52,576 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 52,098 | 0 | 0 | 0 | For |
Fund voting reports, all 64 managers: 18,731,225 for, 9,033,690 against, 47,994 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 0 | 10,016,992 | 0 | 0 | Against |
| T. Rowe Price | 5,013,652 | 0 | 0 | 0 | For |
| Commodore Capital LP | 4,085,581 | 0 | 0 | 0 | For |
| Redmile Group, LLC | 4,051,927 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 3,452,910 | 0 | 0 | 0 | For |
| Wellington | 2,507,434 | 0 | 0 | 0 | For |
| Soleus Capital Management, L.P. | 2,368,719 | 0 | 0 | 0 | For |
| BlackRock | 1,746,978 | 5,004 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 1,621,429 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,598,027 | 0 | 0 | 0 | For |
| State Street | 1,548,262 | 106 | 0 | 0 | For |
| Nikko Asset Management Co., Ltd. | 756,976 | 0 | 0 | 0 | For |
| BESSEMER TRUST Co NATIONAL ASSOCIATION | 611,868 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 588,908 | 0 | 0 | Against |
| Artisan | 585,937 | 0 | 0 | 0 | For |
| WASATCH ADVISORS LP | 569,613 | 0 | 0 | 0 | For |
| Charles Schwab | 551,285 | 0 | 0 | 0 | For |
| Northern Trust | 457,399 | 0 | 0 | 0 | For |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 454,461 | 0 | 0 | 0 | For |
| Woodline Partners LP | 404,968 | 0 | 0 | 0 | For |
| Point72 | 377,441 | 0 | 0 | 0 | For |
| Affinity Asset Advisors, LLC | 350,055 | 0 | 0 | 0 | For |
| Vestal Point Capital, LP | 321,899 | 0 | 0 | 0 | For |
| ArrowMark Colorado Holdings LLC | 314,762 | 0 | 0 | 0 | For |
| Bessemer Trust CO of Delaware, N.A. | 309,450 | 0 | 0 | 0 | For |
Institutional-manager reports, all 155 managers: 38,661,769 for, 11,034,754 against, 18,947 withheld, 3,824 abstained, 46 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Prior year: 100.0% for (May 20, 2024 meeting) ▼ 0.1 pts
Description as filed by funds: Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending November 30, 2025.
NURIX THERAPEUTICS INC.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm”): 64,950,599 for, 85,040 against — passed, per its Form 8-K filed May 19, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending November 30, 2025.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 64 asset managers below reported 27,806,902 for, 13 against, 5,994 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 10,476,011 | 0 | 0 | 0 | For |
| Vanguard | 4,107,266 | 0 | 0 | 0 | For |
| BlackRock | 3,890,098 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,294,671 | 0 | 0 | 0 | For |
| ARK ETF Trust | 1,538,187 | 0 | 0 | 0 | For |
| Charles Schwab | 551,228 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 534,580 | 0 | 0 | 0 | For |
| Artisan | 448,628 | 0 | 0 | 0 | For |
| Hartford | 432,350 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 212,000 | 0 | 0 | 0 | For |
| State Street | 209,596 | 13 | 0 | 0 | For |
| Dimensional | 206,716 | 0 | 0 | 0 | For |
| Equitable | 188,858 | 0 | 0 | 0 | For |
| Victory Capital | 178,799 | 0 | 0 | 0 | For |
| TIAA | 160,469 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 118,386 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 114,985 | 0 | 0 | 0 | For |
| Northwestern Mutual | 95,038 | 0 | 0 | 0 | For |
| Lincoln Financial | 89,715 | 0 | 0 | 0 | For |
| Russell Investments | 85,053 | 0 | 0 | 0 | For |
| John Hancock | 70,384 | 0 | 0 | 0 | For |
| MassMutual | 70,239 | 0 | 0 | 0 | For |
| Tema ETF Trust | 59,146 | 0 | 0 | 0 | For |
| Northern Trust | 52,576 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 52,098 | 0 | 0 | 0 | For |
Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 76,234,799 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 13.74% |
| 2 | Vanguard | 5.39% |
| 3 | BlackRock | 5.10% |
| 4 | T. Rowe Price | 4.32% |
| 5 | ARK ETF Trust | 2.02% |
| 6 | Charles Schwab | 0.72% |
| 7 | WASATCH FUNDS TRUST | 0.70% |
| 8 | Artisan | 0.59% |
| 9 | Hartford | 0.57% |
| 10 | PRIMECAP Odyssey Funds | 0.28% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 13.14% |
| 2 | T. Rowe Price | 6.58% |
| 3 | Commodore Capital LP | 5.36% |
| 4 | Redmile Group, LLC | 5.32% |
| 5 | Deep Track Capital, LP | 4.53% |
| 6 | Wellington | 3.29% |
| 7 | Soleus Capital Management, L.P. | 3.11% |
| 8 | BlackRock | 2.30% |
| 9 | PICTET ASSET MANAGEMENT SA | 2.13% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 2.10% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Redmile Group, LLC | 10,696,314 | 14.03% | Schedule 13G, filed April 24, 2026 |
| FMR (Fidelity) | 10,332,211 | 13.55% | Form 13F, quarter ended March 31, 2025 |
| FMR LLC | 10,306,351 | 13.52% | Proxy statement (DEF 14A), proxy filed March 28, 2025 |
| BlackRock | 7,985,893 | 10.48% | Form 13F, quarter ended March 31, 2025 |
| Baker Bros. Advisors LP | 6,751,565 | 8.86% | Proxy statement (DEF 14A), proxy filed March 28, 2025 |
| Vestal Point Capital, LP | 6,500,000 | 8.53% | Schedule 13G, filed May 15, 2026 |
| Deep Track Capital, LP | 6,345,244 | 8.32% | Schedule 13G, filed May 15, 2026 |
| Vanguard Group | 4,415,122 | 5.79% | Form 13F, quarter ended March 31, 2025 |
| Commodore Capital LP | 3,850,000 | 5.05% | Proxy statement (DEF 14A), proxy filed March 28, 2025 |
| Arthur T. Sands, M.D., Ph.D. | 3,615,207 | 4.74% | Proxy statement (DEF 14A), proxy filed March 28, 2025 |
Percentages above are of 76,234,799 shares outstanding, as reported by NURIX THERAPEUTICS INC. on its Form 10-Q dated February 28, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At NURIX THERAPEUTICS INC.'s shareholder meeting held May 19, 2025, in the 2024-2025 proxy season, 203 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,375 separate fund positions. On the most widely held item on that ballot — To approve, a non-binding advisory basis, the compensation of the Company's named executive… — NURIX THERAPEUTICS INC.'s filing reports the proposal as approved, with 81% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: NURIX THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 19, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from NURIX THERAPEUTICS INC.’s 10-Q dated February 28, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
NURIX THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “NURIX THERAPEUTICS (NRIX) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/nurix-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.